Research

Joseph Leach, MD, PhD was part of a team of UCSF faculty based at the VAMC that examined the association between imaging-based AAA screening - both explicit and implicit - and various outcomes for approximately 1.6 million veterans in the VA health system over ten years (from 2005 to 2015).

Do head knocks eventually lead to Alzheimer's disease? Michael Weiner, MD set out to examine this question in Vietnam veterans.

Although the COVID-19 pandemic has profoundly disrupted many research studies, it has also accelerated development and use of remote assessment tools for cognition. The UCSF Brain Health Registry (BHR), an online research registry of over 100,000 adult volunteers, has been an innovator in this area and has continued to move forward.

The Bay Area Community Of Bay area RAdionuclide imagers (COBRA) meeting returned this year and was hosted at UC Davis on May 25, 2022. COBRA, originally conceived in 2006 by the late Bruce Hasegawa, PhD - brilliant investigator, educator and mentor at UCSF – and Ling Shao.

Recently, investigators from the Cancer Metabolic Imaging and Therapy Lab at the UC San Francisco Department of Radiology and Biomedical Imaging teamed up with the Department of Neurosurgery to identify metabolic alterations linked to this ALT pathway that can be exploited for non-invasive deuterium magnetic resonance spectroscopy (2H-MRS)-based imaging of astrocytomas in vivo.

Recently Brett Elicker, MD, provided commentary on these breakthrough infections, what they are and what they look like. 

Thomas Hope, MD answers some questions about recent developments of prostate-specific membrane antigen PET imaging, or PSMA PET, to provide a more effective imaging test for men who have prostate cancer and what's next. 

UCSF Radiology held its 18th Annual Imaging Research Symposium virtually on November 3, 2021 to highlight the breadth and depth of innovative research being done in the department.

2D and 3D digital mammography - which is better for breast cancer screening? The tomosynthesis mammographic imaging screening trial (TMIST), sponsored by the National Cancer Institute, aims to see which technology performs best in women who have no symptoms.

A team of breast imaging researchers set out to assess the value of targeted breast ultrasound for the primary evaluation of breast symptoms in pregnant women of all ages.